The Covalent Advantage: A New Paradigm for Cell Signaling Mediated by Thiol Reactive Lipid Oxidation Products

Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases

Volumn , Issue , 2006, Pages 343-367

  Dickinson, Dale A ^a   Darley Usmar, Victor M ^b   Landar, Aimee ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Cell signaling by thiol reactive lipid oxidation products; Enzymatic and nonenzymatic lipid peroxidation; Oxidized lipid signaling paradigm the covalent advantage

Indexed keywords

EID: 84889339053     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471973122.ch12     Document Type: Chapter

References (107)

1. Amici C., Belardo G., Rossi A., Santoro M.G. (2001). Activation of I kappa b kinase by herpes simplex virus type 1: A novel target for anti-herpetic therapy. J Biol Chem 276: 28759-28766.
2. Baker C.S., Hall R.J., Evans T.J., Pomerance A., Maclouf J., Creminon C., Yacoub M.H., Polak J.M. (1999). Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19: 646-655.
3. Banerjee M., Kang K.H., Morrow J.D., Roberts L.J., Newman J.H. (1992). Effects of a novel prostaglandin, 8-epi-PGF2 alpha, in rabbit lung in situ. Am J Physiol 263: H660-663.
4. Bea F., Hudson F.N., Chait A., Kavanagh T.J., Rosenfeld M.E. (2003). Induction of glutathione synthesis in macrophages by oxidized low-density lipoproteins is mediated by consensus antioxidant response elements. Circ Res 92: 386-393.
5. Bell-Parikh L.C., Ide T., Lawson J.A., McNamara P., Reilly M., FitzGerald G.A. (2003). Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 112: 945-955.
6. Belton O., Byrne D., Kearney D., Leahy A., Fitzgerald D.J. (2000). Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102: 840-845.
7. Berliner J.A., Subbanagounder G., Leitinger N., Watson A.D., Vora D. (2001). Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 11: 142-147.
8. Bloom D., Dhakshinamoorthy S., Jaiswal A.K. (2002). Site-directed mutagenesis of cysteine to serine in the DNA binding region of Nrf2 decreases its capacity to upregulate antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 21: 2191-2200.
9. Burcham P.C., Fontaine F. (2001). Extensive protein carbonylation precedes acroleinmediated cell death in mouse hepatocytes. J Biochem Mol Toxicol 15: 309-316.
10. Cao C., Matsumura K., Shirakawa N., Maeda M., Jikihara I., Kobayashi S., Watanabe Y. (2001). Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. Eur J Neurosci 13: 1781-1790.
11. Ceaser E.K., Moellering D.R., Shiva S., Ramachandran A., Landar A., Venkartraman A., Crawford J., Patel R., Dickinson D.A., Ulasova E., Ji S., Darley-Usmar V.M. (2004). Mechanisms of signal transduction mediated by oxidized lipids: The role of the electrophile-responsive proteome. Biochem Soc Trans 32: 151-155.
12. Ceaser E.K., Ramachandran A., Levonen A.L., Darley-Usmar V.M. (2003). Oxidized low-density lipoprotein and 15-deoxy-delta 12,14-PGJ2 increase mitochondrial complex I activity in endothelial cells. Am J Physiol Heart Circ Physiol 285: H2298-2308.
13. Chen Y., Morrow J.D., Roberts L.J., 2nd (1999). Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 274: 10863-10868.
14. Cheron A., Peltier J., Perez J., Bellocq A., Fouqueray B., Baud L. (2004). 15-deoxy-Delta12,14-prostaglandin J2 inhibits glucocorticoid binding and signaling in macrophages through a peroxisome proliferator-activated receptor gamma-independent process. J Immunol 172: 7677-7683.
15. Cipollone F., Rocca B., Patrono C. (2004). Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24: 246-255.
16. Clay C.E., Monjazeb A., Thorburn J., Chilton F.H., High K.P. (2002). 15-Deoxydelta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J Lipid Res 43: 1818-1828.
17. Cleeter M.W., Cooper J.M., Darley-Usmar V.M., Moncada S., Schapira A.H. (1994). Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: Implications for neurodegenerative diseases. FEBS Lett 345: 50-54.
18. Cooper C.E., Patel R.P., Brookes P.S., Darley-Usmar V.M. (2002). Nanotransducers in cellular redox signaling: modification of thiols by reactive oxygen and nitrogen species. Trends Biochem Sci 27: 489-492.
19. Cox B., Murphey L.J., Zackert W.E., Chinery R., Graves-Deal R., Boutaud O., Oates J.A., Coffey R.J., Morrow J.D. (2002). Human colorectal cancer cells efficiently conjugate the cyclopentenone prostaglandin, prostaglandin J(2), to glutathione. Biochim Biophys Acta 1584: 37-45.
20. Darley-Usmar V.M., Severn A., O'Leary V.J., Rogers M. (1991). Treatment of macrophages with oxidized low-density lipoprotein increases their intracellular glutathione content. Biochem J 278: 429-434.
21. Davies G., Salter J., Hills M., Martin L.A., Sacks N., Dowsett M. (2003). Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9: 2651-2656.
22. Dempke W., Rie C., Grothey A., Schmoll H.J. (2001). Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127: 411-417.
23. Dickinson D.A., Levonen A.L., Moellering D.R., Arnold E.K., Zhang H., Darley-Usmar V.M., Forman H.J. (2004). Human glutamate cysteine ligase gene regulation through the electrophile response element. Free Radic Biol Med 37: 1152-1159.
24. Dickinson D.A., Moellering D.R., Iles K.E., Patel R.P., Levonen A.L., Wigley A., Darley-Usmar V.M., Forman H.J. (2003). Cytoprotection against oxidative stress and the regulation of glutathione synthesis. Biol Chem 384: 527-537.
25. Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., Yamamoto M., Talalay P. (2002). Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99: 11908-11913.
26. Doll R., Gray R., Hafner B., Peto R. (1980). Mortality in relation to smoking: 22 years'observations on female British doctors. Br Med J 280: 967-971.
27. Doll R., Peto R. (1976). Mortality in relation to smoking: 20 Years' observations on male British doctors. Br Med J 2: 1525-1536.
28. Droge W. (2002). Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95.
29. 3) cells. Biochem Pharmacol 67: 1259-1267.
30. Fang J., Sawa T., Akaike T., Greish K., Maeda H. (2004). Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 109: 1-8.
31. Forman H.J., Torres M. (2001). Redox signaling in macrophages. Mol Aspects Med 22: 189-216.
32. Fukagawa N.K., Timblin C.R., Buder-Hoffman S., Mossman B.T. (2000). Strategies for evaluation of signaling pathways and transcription factors altered in aging. Antioxid Redox Signal 2: 379-389.
33. Gamcsik M.P., Bierbryer R.G., Millis K.K. (2004). Noninvasive monitoring of glutathione turnover in perfused MCF-7 cells. Free Radic Biol Med 37: 961-968.
34. Ghezzi P., Bonetto V. (2003). Redox proteomics: Identification of oxidatively modified proteins. Proteomics 3: 1145-1153.
35. Giles N.M., Giles G.I., Jacob C. (2003a). Multiple roles of cysteine in biocatalysis. Biochem Biophys Res Commun 300: 1-4.
36. Giles N.M., Watts A.B., Giles G.I., Fry F.H., Littlechild J.A., Jacob C. (2003b). Metal and redox modulation of cysteine protein function. Chem Biol 10: 677-693.
37. Glantz S.A., Parmley W.W. (1991). Passive smoking and heart disease: Epidemiology, physiology, and biochemistry. Circulation 83: 1-12.
38. 2-dependent activation of GCLC-ARE4 reporter occurs by mitogen-activated protein kinase pathways without oxidation of cellular glutathione or thioredoxin-1. J Biol Chem 279: 5837-5845.
39. Gotoh N., Graham A., Nikl E., Darley-Usmar V.M. (1993). Inhibition of glutathione synthesis increases the toxicity of oxidized low-density lipoprotein to human monocytes and macrophages. Biochem J 296: 151-154.
40. Griendling K.K., Sorescu D., Lassegue B., Ushio-Fukai M. (2000). Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183.
41. Gryglewski R.J., Chlopicki S., Uracz W., Marcinkiewicz E. (2001). Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation. Med Sci Monit 7: 1-16.
42. Hanna I.R., Taniyama Y., Szocs K., Rocic P., Griendling K.K. (2002). NAD(P)H oxidasederived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 4: 899-914.
43. Hubatsch I., Mannervik B., Gao L., Roberts L.J., Chen Y., Morrow J.D. (2002). The cyclopentenone product of lipid peroxidation, 15-A(2t)-isoprostane (8-isoprostaglandin A(2)), is efficiently conjugated with glutathione by human and rat glutathione transferase A4-4. Chem Res Toxicol 15: 1114-1118.
44. Ischiropoulos H. (1998). Living and dying with reactive species. Focus on "peroxynitrite induces apoptosis of HL-60 cells by activation of a caspase-3 family protease." Am J Physiol 274: C853-C854.
45. Itoh K., Mochizuki M., Ishii Y., Ishii T., Shibata T., Kawamoto Y., Kelly V., Sekizawa K., Uchida K., Yamamoto M. (2004). Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-delta(12,14)-prostaglandin J(2). Mol Cell Biol 24: 36-45.
46. Itoh K., Wakabayashi N., Katoh Y., Ishii T., O'Connor T., Yamamoto M. (2003). Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 8: 379-391.
47. Kim S.O., Merchant K., Nudelman R., Beyer W.F., Jr., Keng T., DeAngelo J., Hausladen A., Stamler J.S. (2002). OxyR: A molecular code for redox-related signaling. Cell 109: 383-396.
48. Koppal T., Petrova T.V., Van Eldik L.J. (2000). Cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells." Brain Res 867: 115-121.
49. Landar A., Darley-Usmar V.M. (2003). Nitric oxide and cell signaling; modulation of redox tone and protein modification. Amino Acids 25: 313-321.
50. Law M.R., Morris J.K., Wald N.J. (1997). Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. Br Med J 315: 973-980.
51. Lee T.S., Tsai H.L., Chau L.Y. (2003). Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxydelta 12,14-prostaglandin J2. J Biol Chem 278: 19325-19330.
52. Leris C., Mokbel K. (2001). The prevention of breast cancer: An overview. Curr Med Res Opin 16: 252-257.
53. Levonen A.L., Dickinson D.A., Moellering D.R., Mulcahy R.T., Forman H.J., Darley-Usmar V.M. (2001b). Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 21: 1846-1851.
54. Levonen A.L., Landar A., Ramachandran A., Ceaser E.K., Dickinson D.A., Zanoni G., Morrow J.D., Darley-Usmar V.M. (2004). Cellular mechanisms of redox cell signalling: Role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 378: 373-382.
55. Levonen A.L., Patel R.P., Brookes P., Go Y.M., Jo H., Parthasarathy S., Anderson P.G., Darley-Usmar V.M. (2001a). Mechanisms of cell signaling by nitric oxide and peroxynitrite: from mitochondria to MAP kinases. Antioxid Redox Signal 3: 215-229.
56. Maggi L.B., Jr., Sadeghi H., Weigand C., Scarim A.L., Heitmeier M.R., Corbett J.A. (2000). Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shock-dependent and-independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49: 346-355.
57. Marathe G.K., Zimmerman G.A., Prescott S.M., McIntyre T.M. (2002). Activation of vascular cells by PAF-like lipids in oxidized LDL. Vascul Pharmacol 38: 193-200.
58. Marshall H.E., Merchant K., Stamler J.S. (2000). Nitrosation and oxidation in the regulation of gene expression. Faseb J 14: 1889-1900.
59. Matsumoto A., Comatas K.E., Liu L., Stamler J.S. (2003). Screening for nitric oxidedependent protein-protein interactions. Science 301: 657-661.
60. McMahon M., Itoh K., Yamamoto M., Hayes J.D. (2003). Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278: 21592-21600.
61. Milne G.L., Musiek E.S., Morrow J.D. (2005). The cyclopentenone (A2/J2) isoprostanes-Unique, highly reactive products of arachidonate peroxidation. Antioxid Redox Signal 7: 210-220.
62. Moellering D.R., Levonen A.L., Go Y.M., Patel R.P., Dickinson D.A., Forman H.J., Darley-Usmar V.M. (2002). Induction of glutathione synthesis by oxidized low-density lipoprotein and 1-palmitoyl-2-arachidonyl phosphatidylcholine: Protection against quinone-mediated oxidative stress. Biochem J 362: 51-59.
63. Moore K.P., Darley-Usmar V., Morrow J., Roberts L.J. II (1995). Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite." Circ Res 77: 335-341.
64. Moore K.P., Holt S.G., Patel R.P., Svistunenko D.A., Zackert W., Goodier D., Reeder B.J., Clozel M., Anand R., Cooper C.E., Morrow J.D., Wilson M.T., Darley-Usmar V., Roberts L.J., 2nd. (1998). A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysisinduced renal failure. J Biol Chem 273: 31731-31737.
65. Morrow J.D. (2005). Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25: 279-286.
66. Mullally J.E., Moos P.J., Edes K., Fitzpatrick F.A. (2001). Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 276: 30366-30373.
67. Na H.K., Surh Y.J. (2003). Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 66: 1381-1391.
68. Nardini M., Finkelstein E.L., Reddy S., Valacchi G., Traber M., Cross C.E., van der Vliet A. (2002). Acrolein induced cytotoxicity in cultured human bronchial epithelial cells. Modulation by alpha-tocopherol and ascorbic acid. Toxicology 170: 173-185.
69. Nguyen T., Sherratt P.J., Huang H.C., Yang C.S., Pickett C.B. (2003a). Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem 278: 4536-4541.
70. Nguyen T., Sherratt P.J., Pickett C.B. (2003b). Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Ann Rev Pharmacol Toxicol. 43: 233-260.
71. Okahara K., Sun B., Kambayashi J. (1998). Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 18: 1922-1926.
72. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. (1989). Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86: 1372-1376.
73. Patel R.P., Moellering D., Murphy-Ullrich J., Jo H., Beckman J.S., Darley-Usmar V.M. (2000). Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 28: 1780-1794.
74. Pratico D., Lawson J.A., Rokach J., FitzGerald G.A. (2001). The isoprostanes in biology and medicine. Trends Endocrinol Metab 12: 243-247.
75. Pratico D., Rokach J., Lawson J., FitzGerald G.A. (2004). F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 128: 165-171.
76. Raju J., Bird R.P. (2003). Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor beta and cyclooxygenase isoforms in Zucker obese (fa/fa) rats. Cancer Res 63: 6595-6601.
77. Ramachandran A., Levonen A.L., Brookes P.S., Ceaser E., Shiva S., Barone M.C., Darley-Usmar V. (2002). Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic Biol Med 33: 1465-1474.
78. Rhee S.G., Bae Y.S., Lee S.R., Kwon J. (2000). Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE 2000: PE1.
79. Rikitake Y., Hirata K., Kawashima S., Takeuchi S., Shimokawa Y., Kojima Y., Inoue N., Yokoyama M. (2001). Signaling mechanism underlying COX-2 induction by lysophosphatidylcholine. Biochem Biophys Res Commun 281: 1291-1297.
80. Roberts L.J., 2nd, Brame C.J., Chen Y., Morrow J.D. (1999). Novel eicosanoids: Isoprostanes and related compounds. Methods Mol Biol 120: 257-285.
81. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., Santoro M.G. (2000). Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103-108.
82. Rouzer C.A., Marnett L.J. (2003). Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem Rev 103: 2239-2304.
83. Sanchez-Gomez F.J., Cernuda-Morollon E., Stamatakis K., Perez-Sala D. (2004). Protein thiol modification by 15-deoxy-Delta12,14-prostaglandin J2 addition in mesangial cells: Role in the inhibition of pro-inflammatory genes. Mol Pharmacol 66: 1349-1358.
84. Schonbeck U., Sukhova G.K., Graber P., Coulter S., Libby P. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291.
85. Schulz E., Anter E., Keaney J.F., Jr. (2004). Oxidative stress, antioxidants, and endothelial function. Curr Med Chem 11: 1093-1104.
86. Sheehan D., Meade G., Foley V.M., Dowd C.A. (2001). Structure, function and evolution of glutathione transferases: Implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J 360: 1-16.
87. Shen L., Sevanian A. (2001). OxLDL induces macrophage gamma-GCS-HS protein expression: A role for oxLDL-associated lipid hydroperoxide in GSH synthesis. J Lipid Res 42: 813-823.
88. Shibata T., Kondo M., Osawa T., Shibata N., Kobayashi M., Uchida K. (2002). 15-deoxydelta 12,14-prostaglandin J2: A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 277: 10459-10466.
89. Shibata T., Yamada T., Ishii T., Kumazawa S., Nakamura H., Masutani H., Yodoi J., Uchida K. (2003a). Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem 278: 26046-26054.
90. Shibata T., Yamada T., Kondo M., Tanahashi N., Tanaka K., Nakamura H., Masutani H., Yodoi J., Uchida K. (2003b). An endogenous electrophile that modulates the regulatory mechanism of protein turnover: Inhibitory effects of 15-deoxy-delta(12,14)-prostaglandin J2 on proteasome. Biochemistry 42: 13960-13968.
91. 2 is used as oxidant. Biochim Biophys Acta 1392: 23-40.
92. Stamler J.S., Lamas S., Fang F.C. (2001). Nitrosylation. the prototypic redox-based signaling mechanism. Cell 106: 675-683.
93. Straus D.S., Glass C.K. (2001). Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med Res Rev 21: 185-210.
94. Subbanagounder G., Watson A.D., Berliner J.A. (2000). Bioactive products of phospholipid oxidation: Isolation, identification, measurement and activities. Free Radic Biol Med 28: 1751-1761.
95. Subbanagounder G., Wong J.W., Lee H., Faull K.F., Miller E., Witztum J.L., Berliner J.A. (2002). Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis: Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem 277: 7271-7281.
96. Uchida K. (2003). 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog Lipid Res 42: 318-343.
97. Wild A.C., Mulcahy R.T. (2000). Regulation of gamma-glutamylcysteine synthetase subunit gene expression: Insights into transcriptional control of antioxidant defenses. Free Radic Res 32: 281-301.
98. Willett W.C., Green A., Stampfer M.J., Speizer F.E., Colditz G.A., Rosner B., Monson R.R., Stason W., Hennekens C.H. (1987). Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. New Engl J Med 317: 1303-1309.
99. Willson T.M., Lehmann J.M., Kliewer S.A. (1996). Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann N Y Acad Sci 804: 276-283.
100. Witztum J.L., Berliner J.A. (1998). Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 9: 441-448.
101. Xu D., Rovira I.I., Finkel T. (2002). Oxidants painting the cysteine chapel: Redox regulation of PTPs. Dev Cell 2: 251-252.
102. Yin H., Porter N.A. (2005). New insights regarding the autoxidation of polyunsaturated fatty acids. Antioxid Redox Signal 7: 170-184.
103. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. (1989). Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095.
104. Zhang X., Lu L., Dixon C., Wilmer W., Song H., Chen X., Rovin B.H. (2004). Stress protein activation by the cyclopentenone prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in human mesangial cells. Kidney Int 65: 798-810.
105. Zhuang H., Kim Y.S., Namiranian K., Dore S. (2003a). Prostaglandins of J series control heme oxygenase expression: Potential significance in modulating neuroinflammation. Ann NY Acad Sci 993: 208-216; discussion 287-288.
106. Zhuang H., Pin S., Li X., Dore S. (2003b). Regulation of heme oxygenase expression by cyclopentenone prostaglandins. Exp Biol Med (Maywood) 228: 499-505.
107. Zipper L.M., Mulcahy R.T. (2000). Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. Biochem Biophys Res Commun 278: 484-492.